leisure time -WSS

leisure time

author：fashion 2025-09-30 00:34:30 - browse：5

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Cue Health's Covid

hotspot

WSS

Health care needs a new profession: neuroimaging counseling

Orangutan used medicinal plant to treat wound, first time ever seen

Listen: Biogen's potential pivot, & Illumina's next chapter

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

FTC falls short on scrutinizing hospital mergers, study says

Q&A: Jennifer Adair on making gene therapy available globally

focus

leisure time

focus

Virginia high school admissions case could be legal follow

NIH nominee Bertagnolli will get October confirmation hearing

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why does health care cost so much? A reading guide

Apple is now the first public company to be valued at $3 trillion

Why does health care cost so much? A reading guide

Continuity nursing helped my family in our darkest PICU moments

Element Biosciences CEO lays out genome sequencing strategy

Medicare proposal to cover medical devices draws a mixed reaction

MultiPlan and major insurers sued for alleged medical price

explore

What drug price negotiations mean for Medicare Part D

Stem cell treatment guidelines are released by FDA

House transparency, PBM reform bill gains bipartisan support

FTC falls short on scrutinizing hospital mergers, study says

Humana sues Biden admin over Medicare Advantage audit rule

Cholera vaccine supply gets boost as demand surges globally

hotspot

hotspot

hotspot

hotspot